Cargando…
Canakinumab and Lung Cancer: Intriguing, but Is It Real?
The relationship between inflammation and cancer is complicated. This editorial calls attention to intriguing findings of the CANTOS trial, which was designed to test the hypothesis that an anti‐inflammatory intervention could reduce the incidence of heart attacks, stroke, or cardiovascular death in...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AlphaMed Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067938/ https://www.ncbi.nlm.nih.gov/pubmed/29666299 http://dx.doi.org/10.1634/theoncologist.2018-0116 |
| _version_ | 1783343192150638592 |
|---|---|
| author | Chabner, Bruce A. Nabel, Christopher S. |
| author_facet | Chabner, Bruce A. Nabel, Christopher S. |
| author_sort | Chabner, Bruce A. |
| collection | PubMed |
| description | The relationship between inflammation and cancer is complicated. This editorial calls attention to intriguing findings of the CANTOS trial, which was designed to test the hypothesis that an anti‐inflammatory intervention could reduce the incidence of heart attacks, stroke, or cardiovascular death in patients with elevated C‐reactive protein. |
| format | Online Article Text |
| id | pubmed-6067938 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | AlphaMed Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-60679382018-08-05 Canakinumab and Lung Cancer: Intriguing, but Is It Real? Chabner, Bruce A. Nabel, Christopher S. Oncologist Editorial The relationship between inflammation and cancer is complicated. This editorial calls attention to intriguing findings of the CANTOS trial, which was designed to test the hypothesis that an anti‐inflammatory intervention could reduce the incidence of heart attacks, stroke, or cardiovascular death in patients with elevated C‐reactive protein. AlphaMed Press 2018-04-17 2018-06 /pmc/articles/PMC6067938/ /pubmed/29666299 http://dx.doi.org/10.1634/theoncologist.2018-0116 Text en © AlphaMed Press 2018 |
| spellingShingle | Editorial Chabner, Bruce A. Nabel, Christopher S. Canakinumab and Lung Cancer: Intriguing, but Is It Real? |
| title | Canakinumab and Lung Cancer: Intriguing, but Is It Real? |
| title_full | Canakinumab and Lung Cancer: Intriguing, but Is It Real? |
| title_fullStr | Canakinumab and Lung Cancer: Intriguing, but Is It Real? |
| title_full_unstemmed | Canakinumab and Lung Cancer: Intriguing, but Is It Real? |
| title_short | Canakinumab and Lung Cancer: Intriguing, but Is It Real? |
| title_sort | canakinumab and lung cancer: intriguing, but is it real? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067938/ https://www.ncbi.nlm.nih.gov/pubmed/29666299 http://dx.doi.org/10.1634/theoncologist.2018-0116 |
| work_keys_str_mv | AT chabnerbrucea canakinumabandlungcancerintriguingbutisitreal AT nabelchristophers canakinumabandlungcancerintriguingbutisitreal |